<DOC>
	<DOCNO>NCT01470144</DOCNO>
	<brief_summary>This open-label , nonrandomized extension study AC-066A301 . The study assess safety tolerability ACT-385781A providing mean continue treatment end participation study AC-066A301 .</brief_summary>
	<brief_title>Epoprostenol Injection Patients With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>1 . Signed informed consent prior initiation studymandated procedure 2 . Patients complete participation study AC066A301 3 . Patients obtain access commercial EFI time end participation study AC066A301 1 . Patients prematurely discontinue study drug study AC066A301 2 . Patients continue treatment EFI longer consider appropriate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>